Hybrid Hearing on “Examining Emergent BioSolutions’ Failure to Protect Public Health and Public Funds”

Wednesday, May 19, 2021 - 10:30am
Select one, Washington, DC 20515
Hybrid Hearing on “Examining Emergent BioSolutions’ Failure to Protect Public Health and Public Funds”



On Wednesday, May 19, 2021, the Select Subcommittee on the Coronavirus Crisis, chaired by Rep. James E. Clyburn, will hold a hybrid in-person / remote hearing with Mr. Robert Kramer, President and Chief Executive Officer of Emergent BioSolutions, Inc. (Emergent), and Mr. Fuad El-Hibri, Executive Chairman of Emergent.  On April 19, 2021, the Select Subcommittee and the Committee on Oversight and Reform opened a joint investigation into Emergent.


The hearing will examine how Emergent’s failure to maintain its manufacturing facilities, train its staff, and comply with Food and Drug Administration standards led to the destruction of millions of doses of coronavirus vaccines, including up to 15 million doses of the Johnson & Johnson vaccine, and how these failures may impact vaccination efforts.  It will also explore the Trump Administration’s decision to award Emergent contracts worth hundreds of millions of dollars to manufacture coronavirus vaccines, despite warnings that the company could not be relied upon to quickly and safely manufacture vaccines during a pandemic.


The hearing will also address how Emergent used its political connections to acquire lucrative manufacturing contracts and significantly raised its prices to the federal government in the years before the pandemic.  These practices, which coincided with increased shareholder profits and executive pay, contributed to shortages of critical supplies in the early months of the coronavirus pandemic.


Mr. Faud El-Hibri
Executive Chairman of the Board of Directors, Emergent BioSolutions, Inc.

Mr. Robert G. Kramer
President and Chief Executive Officer, Emergent BioSolutions, Inc.

117th Congress